We further investigated whether co-encapsulationof the therapeuticanti-PD-1 antibody or OX40L in the hydrogel could enhance the effectsof Dox and cGAMPnp in a neoadjuvant immunotherapy setting paired withsurgery, aiming to generate a potent immune response and prevent cancerrecurrence post tumor resection (Figure 7C). The gene discussed is TNFSF4; the disease is neoplasm.